Towards a vaccine for Cryptococcus neoformans: Principles and caveats

FEMS Yeast Research

Volumn 6, Issue 4, 2006, Pages 525-536

  Datta, Kausik ^a   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody mediated immunity; Cryptococcus neoformans; Vaccine

Indexed keywords

ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; DIPHTHERIA VACCINE; FUNGUS VACCINE; GLUCURONOXYLOMANNAN; MONOCLONAL ANTIBODY; POLYSACCHARIDE VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOMODULATION; INFECTION PREVENTION; INFECTION RESISTANCE; INFECTION RISK; INFLAMMATION; NONHUMAN; PHAGOCYTOSIS; SHORT SURVEY; SURVIVAL;

ANIMALS; ANTIBODIES, FUNGAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG DESIGN; FUNGAL VACCINES; HUMANS; MICE;

FILOBASIDIELLA NEOFORMANS;

EID: 33646568758     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/j.1567-1364.2006.00073.x     Document Type: Short Survey

References (73)

1. Abadi J Friedman J Mageed RA Jefferis R Rodriguez-Barradas MC Pirofski L 1998 Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of V(H)3 gene segment usage J Infect Dis 178 707 716
2. Alugupalli KR Gerstein RM Chen J Szomolanyi-Tsuda E Woodland RT Leong JM 2003 The resolution of relapsing fever borreliosis requires IgM and is concurrent with expansion of B1b lymphocytes J Immunol 170 3819 3827
3. Ashkar AA Rosenthal KL 2002 Toll-like receptor 9, CpG DNA and innate immunity Curr Mol Med 2 545 556
4. Banerjee U Datta K Majumdar T Gupta K 2001 Cryptococcosis in India the awakening of a giant? Med Mycol 39 51 67
5. Batzloff MR Hayman WA Davies MR Zeng M Pruksakorn S Brandt ER Good MF 2003 Protection against group A streptococcus by immunization with J8-diphtheria toxoid contribution of J8- and diphtheria toxoid-specific antibodies to protection J Infect Dis 187 1598 1608
6. Beenhouwer DO Shapiro S Feldmesser M Casadevall A Scharff MD 2001 Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcusneoformans Infect Immun 69 6445 6455
7. Beenhouwer DO May RJ Valadon P Scharff MD 2002 High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library J Immunol 169 6992 6999
8. Biondo C Beninati C Delfino D Oggioni M Mancuso G Midiri A Bombaci M Tomaselli G Teti G 2002 Identification and cloning of a cryptococcal deacetylase that produces protective immune responses Infect Immun 70 2383 2391
9. Black S Shinefield H Fireman B et al 2000 Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group Pediatr Infect Dis J 19 187 195
10. Brown JS Hussell T Gilliland SM Holden DW Paton JC Ehrenstein MR Walport MJ Botto M 2002 The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice Proc Natl Acad Sci USA 99 16969 16974
11. Burns T Abadi M Pirofski LA 2005 Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide Infect Immun 73 4530 4538
12. Casadevall A Perfect JR 1998 Cryptococcus neoformans American Society of Microbiology Press Washington, DC
13. Casadevall A Pirofski LA 1999 Host-pathogen interactions redefining the basic concepts of virulence and pathogenicity Infect Immun 67 3703 3713
14. Casadevall A Pirofski LA 2003a Antibody-mediated regulation of cellular immunity and the inflammatory response Trends Immunol 24 474 478
15. Casadevall A Pirofski LA 2003b The damage-response framework of microbial pathogenesis Nat Rev Microbiol 1 17 24
16. Casadevall A Pirofski LA 2004 New concepts in antibody-mediated immunity Infect Immun 72 6191 6196
17. Casadevall A Pirofski LA 2005 Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans Curr Mol Med 5 421 433
18. Casadevall A Mukherjee J Devi SJ Schneerson R Robbins JB Scharff MD 1992 Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection J Infect Dis 165 1086 1093
19. Casadevall A Feldmesser M Pirofski LA 2002 Induced humoral immunity and vaccination against major human fungal pathogens Curr Opin Microbiol 5 386 391
20. Cassone A De BF Torososantucci A 2005 An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis Curr Mol Med 5 377 382
21. Chang Q Abadi J Alpert P Pirofski L 2000 A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons J Infect Dis 181 1313 1321
22. Chang Q Abadi J Rosenberg M Pirofski LA 2004 VH3 gene expression in children with HIV infection J Infect 49 274 282
23. Chen LC Goldman DL Doering TL Pirofski L Casadevall A 1999 Antibody response to Cryptococcus neoformans proteins in rodents and humans Infect Immun 67 2218 2224
24. Chong Y Ikematsu H Kikuchi K Yamamoto M Murata M Nishimura M Nabeshima S Kashiwagi S Hayashi J 2004 Selective CD27+(memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients AIDS Res Hum Retroviruses 20 219 226
25. Currie BP Casadevall A 1994 Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York city Clin Infect Dis 19 1029 1033
26. DeShaw M Pirofski LA 1995 Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+and HIV- individuals Clin Exp Immunol 99 425 432
27. Devi SJ 1996 Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model Vaccine 14 841 844
28. Devi SJ Schneerson R Egan W Ulrich TJ Bryla D Robbins JB Bennett JE 1991 Cryptococcus neoformans serotype a glucuronoxylomannan-protein conjugate vaccines synthesis, characterization, and immunogenicity Infect Immun 59 3700 3707
29. Diamond MS Shrestha B Marri A Mahan D Engle M 2003 B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus J Virol 77 2578 2586
30. Dromer F Aucouturier P Clauvel JP Saimot G Yeni P 1988a Cryptococcus neoformans antibody levels in patients with AIDS Scand J Infect Dis 20 283 285
31. Dromer F Yeni P Charreire J 1988b Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice Immunogenetics 28 417 424
32. Fleuridor R Zhong Z Pirofski L 1998 A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis J Infect Dis 178 1213 1216
33. Fleuridor R Lyles RH Pirofski L 1999 Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis J Infect Dis 180 1526 1535
34. Fleuridor R Lees A Pirofski L 2001 A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection J Immunol 166 1087 1096
35. Garcia-Hermoso D Janbon G Dromer F 1999 Epidemiologic evidence for dormant Cryptococcus neoformans infection J Clin Microbiol 37 3204 3209
36. Goldman DL Khine H Abadi J Lindenberg DL Pirofski L Niang R Casadevall A 2001 Serologic evidence for Cryptococcus neoformans infection in early childhood Peds 107 e66
37. Harris SL Craig L Mehroke JS et al 1997 Exploring the basis of peptide-carbohydrate crossreactivity evidence for discrimination by peptides between closely related anti-carbohydrate antibodies Proc Natl Acad Sci USA 94 2454 2459
38. Houpt DC Pfrommer GS Young BJ Larson TA Kozel TR 1994 Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan Infect Immun 62 2857 2864
39. Jenny-Avital ER Abadi M 2002 Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy Clin Infect Dis 35 e128 e133
40. Kruetzmann S Rosado MM Weber H et al 2003 Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen J Exp Med 197 939 945
41. Larsen RA Pappas PG Perfect J Aberg JA Casadevall A Cloud GA James R Filler S Dismukes WE 2005 Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis Antimicrob Agents Chemother 49 952 958
42. Maitta RW Datta K Chang Q Luo RX Witover B Subramaniam KS Pirofski LA 2004a Protective and non-protective human IgM monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles Infect Immun 72 4810 4818
43. Maitta RW Datta K Lees A Belouski SS Pirofski LA 2004b Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice Infect Immun 72 196 208
44. Maitta RW Datta K Pirofski LA 2004c Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan Vaccine 22 4062 4068
45. Mansour MK Yauch LE Rottman JB Levitz SM 2004 Protective efficacy of antigenic fractions in mouse models of cryptococcosis Infect Immun 72 1746 1754
46. May RJ Beenhouwer DO Scharff MD 2003 Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates implications for vaccine development J Immunol 171 4905 4912
47. Mendez MJ Green LL Corvalan JR et al 1997 Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice Nat Genet 15 146 156
48. Miyagi K Kawakami K Kinjo Y Uezu K Kinjo T Nakamura K Saito A 2005 CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcusneoformans through induction of interferon-gamma production by CD4+T cells Clin Exp Immunol 140 220 229
49. Monzavi-Karabassi B Cunto-Amesty G Luo P Kieber-Emmons T 2002 Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery Trends Biotechnol 20 207 214
50. Morch C Sonnerborg A Chiodi F 2001 Loss of memory (CD27) B lymphocytes in HIV-1 infection AIDS 15 957 964
51. Murphy JW 1993 Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response Infect Immun 61 4750 4759
52. Murphy JW Schafer F Casadevall A Adesina A 1998 Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans Infect Immun 66 2632 2639
53. Nakouzi A Valadon P Nosanchuk JD Green N Casadevall A 2001 Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and non-protective antibodies Infect Immun 69 3398 3409
54. Nosanchuk JD Rosas AL Casadevall A 1998 The antibody response to fungal melanin in mice J Immunol 160 6026 6031
55. Nosanchuk JD Shoham S Fries BC Shapiro DS Levitz SM Casadevall A 2000 Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient Ann Intern Med 132 205 208
56. Oxman MN Levin MJ Johnson GR et al 2005 A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2271 2284
57. Pietrella D Lupo P Bistoni F Vecchiarelli A 2004 An early imbalance of interleukin 12 influences the adjuvant effect of mannoproteins of Cryptococcus neoformans Cell Microbiol 6 883 891
58. Pirofski LA 2001 Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens Trends Microbiol 9 445 451
59. Pirofski L Lui R DeShaw M Kressel AB Zhong Z 1995 Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine Infect Immun 63 3005 3014
60. Robbins JB Schneerson R Anderson P Smith DH 1996 The 1996 Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide vaccines JAMA 276 1181 1185
61. Rodrigues ML Travassos LR Miranda KR Franzen AJ Rozental S de SW Alviano CS Barreto-Bergter E 2000 Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth Infect Immun 68 7049 7060
62. Rosas AL Nosanchuk JD Casadevall A 2001 Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection Infect Immun 69 3410 3412
63. Singh N Lortholary O Alexander BD et al 2005 An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients Clin Infect Dis 40 1756 1761
64. Spitzer ED Spitzer SG Freundlich LF Casadevall A 1993 Persistence of initial infection in recurrent Cryptococcus neoformans meningitis Lancet 341 595 596
65. Subramaniam K French N Pirofski L 2005 Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans Clin Diagn Lab Immunol 12 1168 1176
66. Taborda CP Casadevall A 2001 Immunoglobulin M efficacy against Cryptococcusneoformans mechanism, dose dependence, and prozone-like effects in passive protection experiments J Immunol 166 2100 2107
67. Taborda CP Rivera J Zaragoza O Casadevall A 2003 More is not necessarily better prozone-like effects in passive immunization with IgG J Immunol 170 3621 3630
68. Valadon P Nussbaum G Oh J Scharff MD 1998 Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide J Immunol 161 1829 1836
69. Vecchiarelli A 2000 Immunoregulation by capsular components of Cryptococcus neoformans Med Mycol 38 407 417
70. Yuan R Casadevall A Scharff MD 1997 T cells cooperate with passive antibody to modify the course of Cryptococcus neoformans in mice Proc Natl Acad Sci USA 94 2483 2488
71. Zhang H Zhong Z Pirofski LA 1997 Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody Infect Immun 65 1158 1164
72. Zhong Z Pirofski LA 1996 Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies Infect Immun 64 3446 3450
73. Zhong Z Pirofski LA 1998 Antifungal activity of a human antiglucuronoxylomannan antibody Clin Diagn Lab Immunol 5 58 64